Investing.com -- Shares of Soligenix (NASDAQ: SNGX) climbed 2.9% following the company’s announcement of promising results for its skin cancer treatment, HyBryteTM, in treating cutaneous T-cell ...

Watch here: Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding ...

Skin biopsy specimens of three lesions on her back were consistent with cutaneous T-cell lymphoma (CTCL). On physical examination, she had erythematous patches and plaques with ill-defined borders ...

The US regulator has cleared Lymphir (denileukin diftitox) for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, resurrecting the ...

High-potency Class I to II topicals are frequently used first line to suppress inflammation and symptoms of itching. These agents are often useful as therapy for stage IA disease, but are often ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its ...

Beckman Research Institute of The City of Hope, Duarte, CA.

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...